Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Eligibility Criteria

• * Ability to comply with the study protocol
• * Willing to use highly effective contraception, if of childbearing potential
• * Diagnosed with follicular lymphoma (FL; Grades 1-3a)
• * Received no prior systemic lymphoma therapy (local radiotherapy is not considered systemic therapy)
• * Inability to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat
• * Grade 3b FL
• * History of transformation of indolent disease to diffuse large B cell lymphoma
• * Any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN)
• * Any prior history of T cell lymphoblastic lymphoma (T-LBL)/ T cell lymphoblastic leukemia (T-ALL)
• * Active or history of central nervous system lymphoma or leptomeningeal infiltration
• * Prior standard or investigational systemic anti cancer therapy for lymphoma. Patients who have received prior XRT will not be excluded
• * History of solid organ transplantation
• * History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies (MAbs)
• * Known or suspected chronic active Epstein-Barr virus (EBV) infection
• * Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
• * Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
• * Active Hepatitis B or Hepatitis C infection
• * HIV positive with CD4 count \<200 and not currently taking antiretroviral therapy
• * History of progressive multifocal leukoencephalopathy (PML)
• * Active autoimmune disease requiring treatment
• * History of autoimmune disease, including, but not limited to: myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
• * Prior allogeneic stem cell transplant (SCT)
• * Significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
• * Major surgery other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study
• * Active central nervous system disease or underlying neurologic disease such as stroke or intracranial hemorrhage within 3 months prior to enrollment, history of seizure disorder, or history of neurogenerative disease
• * History of pneumonitis or interstitial lung disease
• * Pregnant or breastfeeding or intending to become pregnant during the study